Lupus Erythematosus Clinical Trial
Official title:
Treatment of Refractory Systemic Lupus Erythematosus by Injection of Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord
Systemic lupus erythematosus (SLE) is a rare (prevalence: 40- 50/100 000 persons) heterogeneous auto-immune and auto-inflammatory disease (AD), affecting both sexes and all races, with a peak incidence / prevalence among black people and a predilection for women in the 3rd-4th decade of life. SLE is characterized by successive periods of flares and remission, which may all vary in duration and quality. Prognosis of severe forms of SLE, which affect lung, heart or brain in addition to renal involvement, has improved, but still evolution remains pejorative in a subset of patients whose 10 years mortality remains 10-15%, even in tertiary referral centers. For 20 years, no new prospective clinical trial in the course of SLE has demonstrated its effectiveness. New biological therapies have not yet made the long awaited breakthrough in the treatment of severe SLE and only anti-Blys monoclonal antibody has gained indication in moderately active SLE. In addition, serious adverse side effects (progressive multifocal leukoencephalopathy) observed with several biologics in AD patients has dampened their expected benefits. For SLE subjects resistant to 1er or 2nd line conventional treatment, there is a need to develop more effective therapies with fewer long term side effects, based on new immunomodulatory and immunosuppressive strategies. According to their in vitro immunomodulatory properties and ability to induce tissue repair mechanisms, mesenchymal stem cells (MSC) have been proposed as a new therapy for several AD, including SLE. The use of allogeneic umbilical cord-derived MSC is based on experimental and human clinical data, particularly produced by Nanjing team (Pr Sun) in China. It is also logical to select SLE patients with the same severity criteria as those used worldwide to validate the efficacy of anti-Blys therapies. Similarly, the analysis of the expected results should take into account criteria similar or comparable to those used for the pivotal clinical trials. This trial is a unique opportunity to set up collaboration between Saint-Louis APHP, clinical expert center for cell therapy in AD, and University College London for cell manufacturing.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03543839 -
Trial of Belimumab in Early Lupus
|
Phase 4 | |
Terminated |
NCT02080195 -
Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)
|
Phase 1/Phase 2 | |
Completed |
NCT03098823 -
A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE
|
Phase 4 | |
Recruiting |
NCT05545839 -
Transition to Adulthood Through Coaching and Empowerment in Rheumatology
|
N/A | |
Completed |
NCT05098600 -
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
|
||
Completed |
NCT04128579 -
Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis
|
Phase 1 | |
Recruiting |
NCT06161363 -
Description of Compliance With Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus
|
||
Completed |
NCT03421184 -
Dietary Phytoestrogens as Risk Factors for Systemic Lupus Erythematosus
|
N/A | |
Not yet recruiting |
NCT02891213 -
Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus.
|
N/A | |
Completed |
NCT01686555 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
|
Phase 1 | |
Active, not recruiting |
NCT04018222 -
Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic
|
||
Completed |
NCT02747277 -
Analysis of B Cells From Autoimmune Individuals
|
||
Not yet recruiting |
NCT06426316 -
The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology.
|
N/A | |
Recruiting |
NCT04213690 -
A Pilot Study to Explore the Role of Gut Flora in Lupus
|
||
Recruiting |
NCT03913754 -
Psycho-social Consequences of Systemic Lupus Erythematosus
|
||
Recruiting |
NCT06072287 -
The Living With a Long-Term Condition Study
|
||
Completed |
NCT02455089 -
Prognosis Assessment of the Increase of GADD34 Gene Expression for Patient Suffering From Systemic Lupus Erythematosus
|
N/A | |
Completed |
NCT04089930 -
Long-term Immunogenicity of a Live Herpes Zoster Vaccine in Systemic Lupus Erythematosus (SLE) Patients
|
||
Completed |
NCT05945784 -
Exploring Accessible Beauty for Individuals With Upper Extremity Deficits
|
||
Completed |
NCT03253666 -
Nurses' Health Study and Health Professionals Follow-Up Study (Dermatological Component)
|